Physician profile
Jill M Giordano Farmer
NPI 1851548671
$1,179,649.49
in general payments reported to CMS, 2019-2025
28 companies · $254K in 2025
The $254K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88K · 2020: $105K · 2021: $98K · 2022: $105K · 2023: $243K · 2024: $288K · 2025: $254K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $494K · Consulting Fee: $115K · Travel and Lodging: $83K · Honoraria: $76K · Food and Beverage: $13K · Education: $3,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $493,812.46 |
| Consulting Fee | $115,132.38 |
| Travel and Lodging | $83,445.29 |
| Honoraria | $75,657.00 |
| Food and Beverage | $13,472.38 |
| Education | $3,216.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $213,976.92 | 2020-2025 | Nourianz |
| Acadia Pharmaceuticals INC | $206,786.89 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $177,881.98 | 2019-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $164,183.92 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Abbvie INC. | $131,350.72 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $97,465.26 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amneal Pharmaceuticals LLC | $88,078.40 | 2020-2025 | Crexont, Ongentys, Ongentys 50mg Capsules 30 |
| Acorda Therapeutics, INC | $27,036.10 | 2019-2023 | Inbrija |
| Global Kinetics USA Corporation | $20,150.00 | 2022-2023 | Personal Kinetigraph (Pkg) |
| Sunovion Pharmaceuticals INC. | $15,805.37 | 2020-2021 | |
| Tanabe Pharma America, INC. | $11,083.96 | 2023-2024 | |
| Medtronic USA, INC. | $9,430.44 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $6,030.74 | 2021-2024 | Xeomin |
| Medtronic, INC. | $3,503.80 | 2021-2024 | Percept Pc Brainsense |
| Lundbeck LLC | $2,800.17 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adamas Pharmaceuticals, INC. | $2,586.82 | 2021 | |
| Boston Scientific Corporation | $457.07 | 2021-2025 | General - Dbs |
| Supernus Pharmaceuticals, INC. | $323.92 | 2022-2024 | |
| Dr.Reddy'S Laboratories,INC. | $158.00 | 2019 | |
| Revance Therapeutics, INC. | $152.90 | 2024-2025 | Daxi, Daxxify |
| Ge Healthcare | $92.82 | 2025 | |
| Avanir Pharmaceuticals, INC. | $71.19 | 2019-2022 | |
| Ucb, INC. | $66.90 | 2019-2022 | |
| Allergan, INC. | $57.58 | 2021-2022 | |
| Abbott Laboratories | $39.43 | 2021 | |
| Lilly USA, LLC | $38.07 | 2022-2023 | Reyvow, Emgality |
| Biohaven Pharmaceutical Holding Company Ltd. | $26.81 | 2022 | |
| Greenwich Biosciences, INC. | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Giordano Farmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.